BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32729616)

  • 1. Clinical Value of Detecting Anti-Mutated Citrullinated Vimentin, Anti-Cyclic Citrullinated Peptide, Red Cell Distribution Width and 25-Hydroxyvitamin D in the Diagnosis of Rheumatoid Arthritis.
    Tan L; Gong Y; Zhang Q; Zhang H; Lu X; Huang H
    Lab Med; 2021 Jan; 52(1):80-85. PubMed ID: 32729616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J; Zeng T; Zhang X; Tian Y; Wu Y; Yu J; Pei Z; Liu Y; Hu T; Tan L
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?
    Zhu JN; Nie LY; Lu XY; Wu HX
    Clin Chem Lab Med; 2019 Oct; 57(11):1668-1679. PubMed ID: 31141478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis.
    Hu T; Liu Y; Tan L; Huang J; Yu J; Wu Y; Pei Z; Zhang X; Li J; Song L; Dai W; Xiang Y
    Br J Biomed Sci; 2021 Apr; 78(2):67-71. PubMed ID: 32813981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Red Blood Cell Distribution Width and Inflammatory Factors for the Disease Activity in Rheumatoid Arthritis.
    Yunchun L; Yue W; Jun FZ; Qizhu S; Liumei D
    Clin Lab; 2016 Dec; 62(12):2327-2331. PubMed ID: 28164544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
    Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against a mutated citrullinated vimentin in patients with rheumatoid arthritis.
    Nigm DA; Abdel-Lateef HH; Hashim J; Kamal D
    Egypt J Immunol; 2022 Oct; 29(4):184-194. PubMed ID: 36208047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the roles of some immunological biomarkers in the diagnosis of rheumatoid arthritis.
    Khudhair HAA
    J Med Life; 2023 Aug; 16(8):1194-1200. PubMed ID: 38024817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
    Nicaise Roland P; Grootenboer Mignot S; Bruns A; Hurtado M; Palazzo E; Hayem G; Dieudé P; Meyer O; Chollet Martin S
    Arthritis Res Ther; 2008; 10(6):R142. PubMed ID: 19077182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance and diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody and anti-mutated citrullinated vimentin antibodies in patients with serum negative rheumatoid arthritis].
    Qu SJ; Ye H; Jia RL; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):933-936. PubMed ID: 27987492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.